at CNBC.com (Apr 8, 2014)
BioTime (BTX +1.6%) has developed a method to produce seven distinct types of cartilage, bone,...
BioTime (BTX +1.6%) has developed a method to produce seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells using the company's PureStem technology. A lab study showed that BioTime's cells, which can be manufactured on an industrial scale, are "progenitors to diverse skeletal tissues of the human body." BioTime expects to file a request for a Phase I trial in Q1. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at CNBC.com (Dec 20, 2013)
at MarketWatch.com (Jul 13, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs